Myovant Sciences Debt to Equity Ratio 2017-2022 | MYOV

Current and historical debt to equity ratio values for Myovant Sciences (MYOV) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Myovant Sciences debt/equity for the three months ending March 31, 2022 was 0.00.
Myovant Sciences Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2022-03-31 $0.99B $-0.47B -2.10
2021-12-31 $1.04B $-0.43B -2.40
2021-09-30 $1.06B $-0.38B -2.78
2021-06-30 $1.13B $-0.40B -2.82
2021-03-31 $1.08B $-0.35B -3.05
2020-12-31 $1.05B $-0.27B -3.86
2020-09-30 $0.34B $-0.20B -1.68
2020-06-30 $0.26B $-0.14B -1.94
2020-03-31 $0.21B $-0.11B -1.98
2019-12-31 $0.18B $-0.05B -3.65
2019-09-30 $0.17B $0.02B 9.66
2019-06-30 $0.17B $0.08B 2.15
2019-03-31 $0.17B $0.00B 38.91
2018-12-31 $0.16B $0.05B 3.32
2018-09-30 $0.09B $0.07B 1.27
2018-06-30 $0.09B $0.06B 1.57
2018-03-31 $0.08B $0.04B 2.16
2017-12-31 $0.06B $0.08B 0.68
2017-09-30 $0.02B $0.12B 0.15
2017-06-30 $0.02B $0.15B 0.12
2017-03-31 $0.02B $0.17B 0.11
2016-12-31 $0.01B $0.19B 0.04
2016-09-30 $0.04B $-0.04B -1.05
2016-06-30 $0.01B $-0.01B -1.06
2016-03-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.236B $0.231B
Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00